AM 833,
AM-833,
AM833,
Fleroxacin,
Quinodis,
Ro 23 6240,
Ro 23-6240,
Ro 236240,
fleroxacin,
79660-72-3,
Megalone,
Fleroxacino,
Fleroxacinum,
Fleroxicin,
Megalocin,
Quinodis,
Fleroxacine,
6,8-Difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid,
AM-833,
Fleroxacine [French],
Fleroxacinum [Latin],
Fleroxacino [Spanish],
Ro 23-6240,
AM 833,
Fleroxacin (Quinodis),
Ro 23-6240/000,
UNII-N804LDH51K,
CCRIS 3972,
C17H18F3N3O3,
Ro-236240,
BRN 4300996,
N804LDH51K,
CHEBI:31810,
6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid,
6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
NCGC00167558-01,
6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid,
DSSTox_CID_26714,
DSSTox_RID_81846,
DSSTox_GSID_46714,
3-Quinolinecarboxylic acid, 1,4-dihydro-6,8-difluoro-1-(2-fluoroethyl)-7-(4-methyl-1-piperazinyl)-4-oxo-,
3-Quinolinecarboxylic acid, 6,8-difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-,
Megalosin,
Megalocin (TN),
Megalone (TN),
SMR000466302,
CAS-79660-72-3,
FLRX,
Fleroxacin [USAN:BAN:INN:JAN],
SR-01000759379,
Fleroxacin (JAN/USAN/INN),
Fleroxacin,(S),
Fleroxacin [USAN:INN:BAN:JAN],
Fleroxacin(Quinodis),
MFCD00864880,
F0646,
Ro-23-6240/000,
AC1L1FR2,
AC1Q3ZU5,
CHEMBL6273,
SCHEMBL48145,
6,8-difluoro-1-(2-fluoroethyl)-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid,
KSC492E5H,
MLS000759401,
MLS006010715,
AC1Q4N64,
DTXSID1046714,
CTK3J2253,
KS-00000XUW,
XBJBPGROQZJDOJ-UHFFFAOYSA-N,
HMS2090I08,
HMS3715B11,
BCP28939,
HY-B0414,
RKL10075,
ZINC3786299,
Tox21_112553,
ANW-42889,
s2469,
ZINC03786299,
AKOS015907011,
Tox21_112553_1,
API0003278,
CCG-221125,
CS-2518,
DB04576,
KS-5124,
RTR-025289,
VQ10280,
NCGC00167558-02,
6,8-Difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methylpiperazino)-4-oxo-3-quinolinecarboxylic acid,
AM-833;AM833;AM 833,
AN-36581,
CC-28438,
CPD000466302,
SAM001246535,
SC-58138,
AB1010903,
LS-141577,
Ro-236240000,
TR-025289,
FT-0630874,
C13179,
D01716,
Fleroxacin, VETRANAL(TM), analytical standard,
J10168,
AB00640001-02,
AB00640001-03,
AB00640001_04,
660F723,
A839732,
C-21096,
SR-01000759379-2,
SR-01000759379-3,
6,8-difluoro-1-(2-fluoroethyl)-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid,
6,8-bis(fluoranyl)-1-(2-fluoranylethyl)-7-(4-methylpiperazin-1-yl)-4-oxidanylidene-quinoline-3-carboxylic acid,
6,8-Difluoro-1-(2-Fluoroethyl)-1,4-Dihydro-7-(4-Methyl-1-Piperazinyl)-4-Oxo-3-Quinolinecarboxylic Ac,
6,8-difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid-,
6,8-Difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; Megalone,
79660-53-0,
flerofloxacin,
Quinodis (TN),
D06GAM,
Fleroxacin, 98% - 1G 1g,
CID3357,
AM833,
AR-1H0470,
C17-H18-F3-N3-O3,
Ro 236240,
Ro 23 6240,
PF-562271,
B1756,
D016576,
6,8-Difluoro-1-(2-fluoroethyl)1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid,
717907-75-0,
838-67-5,
Methanesulfonamide, N-[3-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-2-pyridinyl]-N-methyl-,